Please login to the form below

Not currently logged in
Email:
Password:

heart failure drug

This page shows the latest heart failure drug news and features for those working in and with pharma, biotech and healthcare.

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline. ... growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene

Latest news

More from news
Approximately 0 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    Drug developers have responded by putting PROs at the heart of their clinical trial designs. ... The performance of Novartis’ heart failure drug Entresto offers one example of that potential.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Ivabradine is thought to be the first drug to work by decreasing the heart rate as a consequence of its action on the If channel that controls the intrinsic pacemaker in ... In the 6, 500-patient SHIFT trial, for example, the drug showed a significant

  • Pharma deals during July 2013 Pharma deals during July 2013

    Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Omecamtiv mecarbil is currently in phase II trials

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...